SANTA ROSA, Calif.--(BUSINESS WIRE)--Since FDA clearance in June 2017, the Sentinel Cerebral Protection System, developed by Claret Medical, has become an emerging standard of care in the U.S. to ...

AACHEN, Germany--(BUSINESS WIRE)--Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of ...

SENTINEL trial to evaluate the Safety and Efficacy of the Sentinel CPS in TAVR population SANTA ROSA, CA. -- Claret Medical, Inc., a developer of innovative solutions for cerebral protection during ...

MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent transcatheter aortic valve replacement with a cerebral protection system experienced fewer ...

The manufacturer of two transcatheter aortic valve technologies that have yet to get US Food and Drug Administration (FDA) clearance announced today that it plans to purchase the company that makes ...

The European Investment Bank (EIB) is providing €20 million in venture-debt financing to German medical-technology company Protembis to develop a next-generation device for protecting the brains of ...

Only CEP Trial Designed as a Superiority Trial using DW-MRI to Demonstrate Effectiveness Against the Currently Approved Sentinel Device NEW YORK & AACHEN, Germany–(BUSINESS WIRE)–April 2, 2024– ...

Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

Protembis GmbH received €20 million (US$21.66 million) in financing from the European Investment Bank to develop its cerebral embolic protection system, Protembo. The intra-aortic filter device ...